MX2010005115A - Anticuerpos anti-factor b y sus usos. - Google Patents

Anticuerpos anti-factor b y sus usos.

Info

Publication number
MX2010005115A
MX2010005115A MX2010005115A MX2010005115A MX2010005115A MX 2010005115 A MX2010005115 A MX 2010005115A MX 2010005115 A MX2010005115 A MX 2010005115A MX 2010005115 A MX2010005115 A MX 2010005115A MX 2010005115 A MX2010005115 A MX 2010005115A
Authority
MX
Mexico
Prior art keywords
factor
antibodies
cnv
amd
antagonists
Prior art date
Application number
MX2010005115A
Other languages
English (en)
Spanish (es)
Inventor
Laura Deforge
Menno Van Lookeren Campagne
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010005115(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2010005115A publication Critical patent/MX2010005115A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010005115A 2007-11-08 2008-11-06 Anticuerpos anti-factor b y sus usos. MX2010005115A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US264807P 2007-11-08 2007-11-08
PCT/US2008/082621 WO2009061910A1 (en) 2007-11-08 2008-11-06 Anti-factor b antibodies and their uses

Publications (1)

Publication Number Publication Date
MX2010005115A true MX2010005115A (es) 2010-05-27

Family

ID=40344464

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005115A MX2010005115A (es) 2007-11-08 2008-11-06 Anticuerpos anti-factor b y sus usos.

Country Status (15)

Country Link
US (4) US8158762B2 (OSRAM)
EP (1) EP2209807A1 (OSRAM)
JP (1) JP2011503094A (OSRAM)
KR (1) KR20100105587A (OSRAM)
CN (1) CN101918444A (OSRAM)
AR (1) AR069233A1 (OSRAM)
AU (1) AU2008323939A1 (OSRAM)
BR (1) BRPI0820343A2 (OSRAM)
CA (1) CA2704973A1 (OSRAM)
CL (1) CL2008003313A1 (OSRAM)
IL (1) IL205577A0 (OSRAM)
MX (1) MX2010005115A (OSRAM)
PE (1) PE20091022A1 (OSRAM)
TW (1) TW200927170A (OSRAM)
WO (1) WO2009061910A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
TWI407953B (zh) * 2011-03-24 2013-09-11 Univ Kaohsiung Medical 用於調節補體因子ｂ（ｃｆｂ）表現的醫藥組合物
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
TWI846166B (zh) 2013-11-15 2024-06-21 美商阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途
TN2018000341A1 (en) 2016-04-04 2020-06-15 Bioverativ Usa Inc ANTl-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF.
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
MX2022013135A (es) 2020-04-20 2022-11-10 Genzyme Corp Anticuerpos anti-factor bb del complemento humanizados y usos de los mismos.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
ES2432112T3 (es) * 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
KR20170002684A (ko) * 2005-11-04 2017-01-06 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
SG172686A1 (en) 2006-03-08 2011-07-28 Archemix Corp Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
CA2678774A1 (en) * 2007-03-01 2008-09-04 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation

Also Published As

Publication number Publication date
EP2209807A1 (en) 2010-07-28
BRPI0820343A2 (pt) 2017-08-22
IL205577A0 (en) 2010-11-30
KR20100105587A (ko) 2010-09-29
JP2011503094A (ja) 2011-01-27
US20120230997A1 (en) 2012-09-13
US8158762B2 (en) 2012-04-17
TW200927170A (en) 2009-07-01
AU2008323939A1 (en) 2009-05-14
US20180037667A1 (en) 2018-02-08
CN101918444A (zh) 2010-12-15
PE20091022A1 (es) 2009-07-16
AR069233A1 (es) 2010-01-06
CA2704973A1 (en) 2009-05-14
CL2008003313A1 (es) 2010-02-05
WO2009061910A1 (en) 2009-05-14
US20160024224A1 (en) 2016-01-28
US20090123469A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
MX2009012422A (es) Prevencion y tratamiento de afecciones del ojo asociadas con su complemento.
SG156649A1 (en) Crig polypeptide for prevention and treatment of complement-associated disorders
MX2010005115A (es) Anticuerpos anti-factor b y sus usos.
MY161495A (en) Virus like particle compositions and methods of use
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
MX351152B (es) Compstatina y analogos de la misma para tratar trastornos oculares.
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
CY1113291T1 (el) Συνθεσεις και μεθοδοι για sirna αναστολη της αγγειογενεσης
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
TW200736275A (en) Methods and compositions for treating allergic diseases
MX2009011533A (es) Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
PH12013500577B1 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
WO2011071574A3 (en) Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
MX2010010303A (es) Nuevos compuestos de acido ribonucleico de pequeña interferencia para inhibir rtp801.
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
TW200942535A (en) Novel compounds as cannabinoid receptor ligands
MX2022006145A (es) Anticuerpos trem2 y usos de estos.
WO2008044217A3 (en) 2-aminocarbonyl-pyridine derivatives
WO2007133800A3 (en) Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration
WO2006039327A3 (en) Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve
IN2012DN03361A (OSRAM)
WO2008048675A3 (en) Treatment for age-related macular degeneration and other diseases of the eye
TW200833248A (en) Bisoximes as fungicides
HK1255695A1 (zh) 用於治疗眼睑下垂的组合物和方法